Advertisement

Journal of Medical Toxicology

, Volume 9, Issue 4, pp 347–354 | Cite as

The Role of Chelation in the Treatment of Arsenic and Mercury Poisoning

  • Michael J KosnettEmail author
Proceedings

Abstract

Chelation for heavy metal intoxication began more than 70 years ago with the development of British anti-lewisite (BAL; dimercaprol) in wartime Britain as a potential antidote the arsenical warfare agent lewisite (dichloro[2-chlorovinyl]arsine). DMPS (unithiol) and DMSA (succimer), dithiol water-soluble analogs of BAL, were developed in the Soviet Union and China in the late 1950s. These three agents have remained the mainstay of chelation treatment of arsenic and mercury intoxication for more than half a century. Animal experiments and in some instances human data indicate that the dithiol chelators enhance arsenic and mercury excretion. Controlled animal experiments support a therapeutic role for these chelators in the prompt treatment of acute poisoning by arsenic and inorganic mercury salts. Treatment should be initiated as rapidly as possible (within minutes to a few hours), as efficacy declines or disappears as the time interval between metal exposure and onset of chelation increases. DMPS and DMSA, which have a higher therapeutic index than BAL and do not redistribute arsenic or mercury to the brain, offer advantages in clinical practice. Although chelation following chronic exposure to inorganic arsenic and inorganic mercury may accelerate metal excretion and diminish metal burden in some organs, potential therapeutic efficacy in terms of decreased morbidity and mortality is largely unestablished in cases of chronic metal intoxication.

Keywords

Chelating agents Unithiol Succimer Dimercaprol Arsenic Mercury 

Notes

Acknowledgments

This publication was supported by the cooperative agreement award number 1U61TS000117-04 from the Agency for Toxic Substances and Disease Registry (ATSDR). Its contents are the responsibility of the authors and do not necessarily represent the official views of the Agency for Toxic Substances and Disease Registry (ATSDR).

Conflict of Interest

For the work under consideration for publication, Dr. Kosnett received an honorarium and reimbursement for travel through the ACMT/ATSDR Cooperative Agreement.

References

  1. 1.
    Vilensky JA (2002) Dew of death: the story of Lewisite, America’s World War I weapon of mass destruction. Indiana University Press, BloomingtonGoogle Scholar
  2. 2.
    Stocken LA, Thompson RHS (1946) British anti-lewisite. Dithiol compounds as antidotes for arsenic. Biochem J 40:535–548PubMedGoogle Scholar
  3. 3.
    Peters RA, Stocken LA, Thompson RHS (1945) British anti-lewisite (BAL). Nature 156:616–619PubMedCrossRefGoogle Scholar
  4. 4.
    Chiesman WE (1944) Diagnosis and treatment of lesions due to vesicants. Br Med J 2(4359):109–112PubMedCrossRefGoogle Scholar
  5. 5.
    Luetscher JA, Eagle H, Longcope WT, Watson EB (1946) Clinical uses of 2,3-dimercaptopropanol (BAL). VIII. The effect of BAL on the excretion of arsenic in arsenical intoxication. J Clin Investig 25(4):534–540CrossRefGoogle Scholar
  6. 6.
    Carleton AB, Peters RA, Thompson RHS (1948) The treatment of arsenical dermatitis with dimercaptopropanol (BAL). Q J Med 17:49–79PubMedGoogle Scholar
  7. 7.
    Woody NC, Kometani JT (1948) BAL in the treatment of arsenic ingestion of children. Pediatrics 1(3):372–378PubMedGoogle Scholar
  8. 8.
    Petrunkin VE (1956) Synthesis and properties of dimercapto derivatives of alkylsulfonic acids. Ukr Khem Zh 22:603–607Google Scholar
  9. 9.
    Liang Y, Chu C, Tsen Y, Ting K (1957) Studies on antibilharzial drugs. VI. The antidotal effects of sodium dimercaptosuccinate and BAL-glucoside against tartar emetic. Acta Physiol Sin 21:24–32Google Scholar
  10. 10.
    Aposhian HV, Carter DE, Hoover TD, Hsu CA, Maiorino RM, Stine E (1984) DMSA, DMPS, and DMPA—as arsenic antidotes. Fundam Appl Toxicol 4:S58–S70PubMedCrossRefGoogle Scholar
  11. 11.
    Eagle H, Magnuson HJ, Fleischman R (1946) Clinical uses of 2,3 dimercaptopropanol (BAL). I. The systemic treatment of experimental arsenic poisoning (marphasen, lewisite, phenyl arsenoxide) with BAL. J Clin Investig 25:451–466PubMedCrossRefGoogle Scholar
  12. 12.
    Tadlock CH, Aposhian HV (1980) Protection of mice against the lethal effects of sodium arsenite by 2,3-dimercapto-1-propane-sulfonic acid and dimercaptosuccinic acid. Biochem Biophys Res Commun 94:501–507PubMedCrossRefGoogle Scholar
  13. 13.
    Guha Mazumder DN, De BK, Santra A, Ghosh N, Das S, Lahiri S, Das T (2001) Randomized placebo-controlled trial of 2,3-dimercapto-1-propanesulfonate (DMPS) in therapy of chronic arsenicosis due to drinking arsenic-contaminated water. Clin Toxicol 39:665–674CrossRefGoogle Scholar
  14. 14.
    Guha Mazumder DN, Ghoshal UC, Saha J, Santra A, De BK, Chatterjee A et al (1998) Randomized placebo-controlled trial of 2,3-dimercaptosuccinic acid in therapy of chronic arsenicosis due to drinking arsenic-contaminated subsoil water. Clin Toxicol 36:683–690CrossRefGoogle Scholar
  15. 15.
    Nickle RA (1999) Mercury—top of the hit parade for eight years. Drug Chem Toxicol 22(1):129–142PubMedCrossRefGoogle Scholar
  16. 16.
    Longcope WT, Luetscher JA (1949) The use of BAL (British Anti-Lewisite) in the treatment of the injurious effects of arsenic, mercury, and other metallic poisons. Ann Intern Med 31:545–553PubMedCrossRefGoogle Scholar
  17. 17.
    Nielsen JB, Andersen O (1991) Effect of four thiol-containing chelators on disposition of orally administered mercuric chloride. Hum Exp Toxicol 10:423–430PubMedCrossRefGoogle Scholar
  18. 18.
    Wannag A, Aaseth A (1980) The effect of immediate and delayed treatment with 2,3-dimercapto-propane-1-sulphonate on the distribution and toxicity of inorganic mercury in mice and in foetal and adult rats. Acta Pharmacol Toxicol 46:81–88CrossRefGoogle Scholar
  19. 19.
    Planas-Bohne F (1977) The excretion of two renal enzymes as influenced by mercuric chloride and DMPS. In: Brown SS (ed) Clinical chemistry and chemical toxicology of metals. Elsevier, New York, pp 119–122Google Scholar
  20. 20.
    Planas-Bohne F (1981) The effect of 2,3-dimercaptopropane-1-sulfonate and dimercaptosuccinic acid on the distribution and excretion of mercuric chloride in rats. Toxicology 18:275–278CrossRefGoogle Scholar
  21. 21.
    Treatment of Lead-Exposed Children (TLC) Trial Group (2000) Safety and efficacy of succimer in toddlers with blood lead levels of 20–44 Microg/dL. Pediatr Res 48(5):593–599CrossRefGoogle Scholar
  22. 22.
    Smith DR. The scientific basis for chelation: animal studies and lead chelation. J Med Toxicol 2013;9(4). doi: 10.1007/s13181-013-0339-2
  23. 23.
    Berlin M, Rylander R (1964) Increased brain uptake of mercury induced by 2,3-dimercaptopropanol (BAL) in mice exposed to phenylmercuric acetate. J Pharmacol Exp Ther 146:236–240PubMedGoogle Scholar
  24. 24.
    Cichini GM, Petzl DH, Zeitlhofer J, Wolf C, Meisinger V, Strasser K et al (1989) Effekt von DMPS und d-Penicillamin bei inhalativer Intoxikation mit metallischem Quecksilber. Intensivmed Notf Med 26(6):303–306Google Scholar
  25. 25.
    Buchet JP, Lauwerys RR (1989) Influence of 2,3 dimercaptopropane-1-sulfonate and dimercaptosuccinic acid on the mobilization of mercury from tissues of rats pretreated with mercuric chloride, phenylmercury acetate or mercury vapors. Toxicology 54:323–333PubMedCrossRefGoogle Scholar
  26. 26.
    Nerudová J, Cábelková Z, Frantík E, Lukás E, Urban P, Bláha K et al (2000) Mobilization of mercury by DMPS in occupationally exposed workers and in model experiments on rats: evaluation of body burden. Int J Occup Med Environ Health 13:131–146PubMedGoogle Scholar
  27. 27.
    Aposhian HV, Morgan DL, Queen HLS, Maiorino RM, Aposhian MM (2003) Vitamin C, glutathione, or lipoic acid did not decrease brain or kidney mercury in rats exposed to mercury vapor. Clin Toxicol 41:339–347CrossRefGoogle Scholar
  28. 28.
    Bridges CC, Joshee L, Zalups RK (2008) Multi-drug resistance proteins and the renal elimination of inorganic mercury mediated by 2,3-dimercaptopropane-1-sulfonic acid and meso-2,3-dimercaptosuccinic acid. J Pharmacol Exp Ther 324:383–390PubMedCrossRefGoogle Scholar
  29. 29.
    Zalups RK, Bridges CC (2012) Relationships between the renal handling of DMPS and DMSA and the renal handling of mercury. Chem Res Toxicol 25:1825–1838PubMedCrossRefGoogle Scholar
  30. 30.
    Roels HA, Boeck M, Ceulemans E, Lauwerys RR (1991) Urinary excretion of mercury after occupational exposure to mecury vapour and influence of the chelating agent meso-2,3-dimercaptosuccinic acid (DMSA). Brit J Ind Med 48:247–253Google Scholar
  31. 31.
    Gonzalez-Ramirez D, Zuniga-Charles M, Narro-Juarez A, Molina-Recio Y, Hurlbut KM, Dart RC, Aposhian HV (1998) DMPS (2,3-dimercaptopropane-1-sulfonate, Dimaval) decreases the body burden of mercury in humans exposed to mercurous chloride. J Pharmacol Exp Ther 287:8–12PubMedGoogle Scholar

Copyright information

© American College of Medical Toxicology 2013

Authors and Affiliations

  1. 1.Division of Clinical Pharmacology and Toxicology, Department of MedicineUniversity of Colorado School of MedicineDenverUSA

Personalised recommendations